| High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects BP Kleinstiver, V Pattanayak, MS Prew, SQ Tsai, NT Nguyen, Z Zheng, ... Nature 529 (7587), 490-495, 2016 | 2886 | 2016 |
| High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity V Pattanayak, S Lin, JP Guilinger, E Ma, JA Doudna, DR Liu Nature biotechnology 31 (9), 839-843, 2013 | 1905 | 2013 |
| Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection V Pattanayak, CL Ramirez, JK Joung, DR Liu Nature methods 8 (9), 765-770, 2011 | 653 | 2011 |
| Small molecule–triggered Cas9 protein with improved genome-editing specificity KM Davis, V Pattanayak, DB Thompson, JA Zuris, DR Liu Nature chemical biology 11 (5), 316-318, 2015 | 497 | 2015 |
| Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity JP Guilinger, V Pattanayak, D Reyon, SQ Tsai, JD Sander, JK Joung, ... Nature methods 11 (4), 429-435, 2014 | 293 | 2014 |
| Directed evolution and substrate specificity profile of homing endonuclease I-SceI JB Doyon, V Pattanayak, CB Meyer, DR Liu Journal of the American Chemical Society 128 (7), 2477-2484, 2006 | 171 | 2006 |
| Determining the specificities of TALENs, Cas9, and other genome-editing enzymes V Pattanayak, JP Guilinger, DR Liu Methods in enzymology 546, 47-78, 2014 | 100 | 2014 |
| In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites JD Sander, CL Ramirez, SJ Linder, V Pattanayak, N Shoresh, M Ku, ... Nucleic acids research 41 (19), e181-e181, 2013 | 96 | 2013 |
| Engineered CRISPR-Cas9 nucleases JK Joung, B Kleinstiver, V Pattanayak US Patent 9,512,446, 2016 | 95 | 2016 |
| Methods for identifying a target site of a Cas9 nuclease DR Liu, V Pattanayak US Patent 9,163,284, 2015 | 92 | 2015 |
| Engineered transcription activator-like effector (TALE) domains and uses thereof DR Liu, JP Guilinger, V Pattanayak US Patent 9,359,599, 2016 | 78 | 2016 |
| Evaluation and improvement of nuclease cleavage specificity DR Liu, JP Guilinger, V Pattanayak US Patent 9,322,006, 2016 | 67 | 2016 |
| Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients A Al Jurdi, RB Gassen, TJ Borges, IT Lape, L Morena, O Efe, Z Solhjou, ... Kidney International 101 (6), 1282-1286, 2022 | 48 | 2022 |
| Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo” CA Lareau, K Clement, JY Hsu, V Pattanayak, JK Joung, MJ Aryee, ... Nature methods 15 (4), 238-239, 2018 | 48* | 2018 |
| Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito WT Garrood, N Kranjc, K Petri, DY Kim, JA Guo, AM Hammond, ... Proceedings of the National Academy of Sciences 118 (22), e2004838117, 2021 | 40 | 2021 |
| A Code of Ethics for Gene Drive Research GJ Annas, CL Beisel, K Clement, A Crisanti, S Francis, M Galardini, ... The CRISPR Journal 4 (1), 19-24, 2021 | 37 | 2021 |
| SHERLOCK and DETECTR Open a New Frontier in Molecular Diagnostics K Petri, V Pattanayak The CRISPR journal 1 (3), 209-211, 2018 | 29 | 2018 |
| CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation E Konstantinidis, A Molisak, F Perrin, L Streubel-Gallasch, S Fayad, ... Molecular Therapy-Nucleic Acids 28, 450-461, 2022 | 25 | 2022 |
| Non-invasive monitoring for rejection in kidney transplant recipients after SARS-CoV-2 mRNA vaccination A Al Jurdi, RB Gassen, TJ Borges, Z Solhjou, FE Hullekes, IT Lape, O Efe, ... Frontiers in Immunology 13, 838985, 2022 | 23 | 2022 |
| Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects K Petri, DY Kim, KE Sasaki, MC Canver, X Wang, H Shah, H Lee, ... Biorxiv, 2021.04. 05.438458, 2021 | 23 | 2021 |
